Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial

• Published in: Critical care (London, England) Vol. 18; no. 6; p. 713
• Main Authors: Fuernau, Georg, Pöss, Janine, Denks, Daniel, Desch, Steffen, Heine, Gunnar H, Eitel, Ingo, Seiler, Sarah, de Waha, Suzanne, Ewen, Sebastian, Link, Andreas, Schuler, Gerhard, Adams, Volker, Böhm, Michael, Thiele, Holger
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21-12-2014; BioMed Central
• Subjects: Aged; Aged, 80 and over; Biomarkers - blood; Creatinine - blood; Female; Fibroblast Growth Factors - blood; Humans; Intra-Aortic Balloon Pumping; Kaplan-Meier Estimate; Kidney - physiopathology; Logistic Models; Male; Middle Aged; Myocardial Infarction - blood; Myocardial Infarction - complications; Myocardial Infarction - mortality; Myocardial Infarction - physiopathology; Myocardial Infarction - surgery; Proportional Hazards Models; Shock, Cardiogenic - blood; Shock, Cardiogenic - etiology; Shock, Cardiogenic - mortality; Shock, Cardiogenic - physiopathology; Treatment Outcome
• ISSN: 1364-8535; 1466-609X; 1364-8535
• DOI: 10.1186/s13054-014-0713-8

Cardiogenic shock (CS) is the leading cause of death in patients hospitalized with acute myocardial infarction (AMI). Biomarkers might help in risk stratification and understanding of pathophysiology. Preliminary data suggests that patients with CS face a profound increase in the osteocyte-derived hormone fibroblast growth factor 23 (FGF-23), which acts as a negative regulator of serum phosphate levels. The present study aimed to assess the predictive role of FGF-23 for clinical outcome in a large cohort of CS patients with and without renal dysfunction.
In the randomized Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial, 600 patients with CS complicating AMI were assigned to therapy with or without IABP. Our predefined biomarker substudy included 182 patients. Blood sampling was performed in a standardized procedure at three different time points (day 1 (day of admission), day 2 and day 3). Differences in outcome of patients with FGF-23 levelsmedian were compared by log-rank testing. Stepwise logistic regression modeling was performed to identify predictors of death at 30 days and Cox regression analysis for time to death during the first year.
At all three time points, nonsurvivors had significantly higher FGF-23 levels compared to survivors (P<0.001 for all). Patients with FGF-23 levels above the median (395 RU/mL [interquartile range 102;2,395]) were characterized by an increased 30-day mortality and 1-year mortality. In multivariable analysis FGF-23 levels remained independent predictors for 30-day (odds ratio per 10log 1.80, 95% confidence interval (CI) 1.11 to 2.92; P=0.02) and 1-year mortality (hazard ratio 1.50, 95% CI 1.11 to 2.04, P=0.009). After stratifying the patients according to their baseline serum creatinine levels, the negative prognostic association of increased FGF-23 was only significant in those with serum creatinine greater than median.
In CS, high levels of FGF-23 are independently related to a poor clinical outcome. However, this prognostic association appears only to apply in patients with impaired renal function.
ClinicalTrials.gov NCT00491036. Registered 22 June 2007.